ATE403433T1 - Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen - Google Patents

Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen

Info

Publication number
ATE403433T1
ATE403433T1 AT02769372T AT02769372T ATE403433T1 AT E403433 T1 ATE403433 T1 AT E403433T1 AT 02769372 T AT02769372 T AT 02769372T AT 02769372 T AT02769372 T AT 02769372T AT E403433 T1 ATE403433 T1 AT E403433T1
Authority
AT
Austria
Prior art keywords
adenosine
hypoxia
treatment
receptor antagonists
memory disorders
Prior art date
Application number
AT02769372T
Other languages
English (en)
Inventor
Miao-Kun Sun
Daniel Alkon
Original Assignee
Brni Neurosciences Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brni Neurosciences Inst filed Critical Brni Neurosciences Inst
Application granted granted Critical
Publication of ATE403433T1 publication Critical patent/ATE403433T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02769372T 2001-05-08 2002-05-08 Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen ATE403433T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28913701P 2001-05-08 2001-05-08

Publications (1)

Publication Number Publication Date
ATE403433T1 true ATE403433T1 (de) 2008-08-15

Family

ID=23110201

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02769372T ATE403433T1 (de) 2001-05-08 2002-05-08 Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen

Country Status (9)

Country Link
US (1) US20040248909A1 (de)
EP (1) EP1385523B1 (de)
JP (1) JP2004534022A (de)
AT (1) ATE403433T1 (de)
AU (1) AU2002308628A1 (de)
CA (1) CA2446828C (de)
DE (1) DE60228073D1 (de)
ES (1) ES2311626T3 (de)
WO (1) WO2002089736A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US20070078148A1 (en) * 2003-12-09 2007-04-05 Kyowa Hakko Kogyo Co., Ltd. Agents for preventing and/or treating higher brain dysfunctions
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US8784898B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of wound care and treatment
EP2086668B1 (de) 2006-10-25 2016-11-16 Revalesio Corporation Mischvorrichtung und verfahren
CA2667614A1 (en) 2006-10-25 2008-09-25 Revalesio Corporation Method of wound care and treatment
US8784897B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of therapeutic treatment of eyes
US8597689B2 (en) 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US8609148B2 (en) 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
US20090263495A1 (en) * 2007-10-25 2009-10-22 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
BRPI0911757A2 (pt) 2008-05-01 2013-09-17 Revalesio Corp composiÇÕes e mÉtodos para tratar distérbios digestivos.
FR2933753B1 (fr) * 2008-07-08 2011-05-06 Max Power Eolienne
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
WO2011140524A1 (en) 2010-05-07 2011-11-10 Revalesio Corporation Compositions and methods for enhancing physiological performance and recovery time
CA2808189A1 (en) 2010-08-12 2012-02-16 Revalesio Corporation Compositions and methods for treatment of taupathy
US10092591B2 (en) 2014-02-27 2018-10-09 University Of Alaska Fairbanks Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
US10696972B2 (en) * 2015-02-19 2020-06-30 St. Jude Children's Research Hospital, Inc. Method for improving learning
US20210393857A1 (en) * 2018-11-05 2021-12-23 The Regents Of The University Of California Small molecule drugs and methods to accelerate osseointegration

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932424A (en) * 1970-06-15 1976-01-13 Richardson-Merrell Inc. Bis-basic ethers of carbazole
JP3116230B2 (ja) * 1989-02-15 2000-12-11 武田薬品工業株式会社 三環式縮合ピリミジン誘導体
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE4002092A1 (de) * 1990-01-25 1991-08-01 Schulte Schlagbaum Ag Schloss mit durch einschieben einer bereichsweise magnetisierten schluesselkarte freizugebender schliessfunktion
ES2123570T3 (es) * 1991-07-31 1999-01-16 Boehringer Ingelheim Pharma Uso de la molecula de adhesion de leucocitos y endotelios 1 y anticuerpos contra ella en el tratamiento del asma.
US5272269A (en) * 1992-01-16 1993-12-21 The Du Pont Merck Pharmaceutical Company Disubstituted polycyclic systems and preparative methods therefor
US5336769A (en) * 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5292766A (en) * 1992-03-25 1994-03-08 Eli Lilly And Company Method for improving primary memory and/or learning
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
JPH09286936A (ja) * 1996-04-22 1997-11-04 Sumitomo Metal Mining Co Ltd 透明導電膜形成用塗布液、これを用いた透明導電膜及びその形成方法
EP1066036B1 (de) * 1998-02-27 2006-04-26 The Board Of Trustees Of The University Of Illinois Stoffe mit serotoninartiger wirkung zur behandlung der schlafapnoe
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
US6821979B2 (en) * 2002-03-07 2004-11-23 Blanchette Rockefeller Neurosciences Institute Synergistic enhancement of cognitive ability

Also Published As

Publication number Publication date
CA2446828C (en) 2011-01-04
EP1385523A4 (de) 2005-01-26
US20040248909A1 (en) 2004-12-09
DE60228073D1 (de) 2008-09-18
WO2002089736A3 (en) 2003-04-03
EP1385523B1 (de) 2008-08-06
EP1385523A2 (de) 2004-02-04
AU2002308628A1 (en) 2002-11-18
ES2311626T3 (es) 2009-02-16
JP2004534022A (ja) 2004-11-11
CA2446828A1 (en) 2002-11-14
WO2002089736A2 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
ATE403433T1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
ME00275B (me) ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60327335D1 (de) Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties